[HTML][HTML] Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
G Chazan, BJ Solomon - Translational Lung Cancer Research, 2023 - ncbi.nlm.nih.gov
Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
Uniqueness of lung cancer in Southeast Asia
Lung cancer varies between Caucasians and Asians. There have been differences recorded
in the epidemiology, genomics, standard therapies and outcomes, with variations according …
in the epidemiology, genomics, standard therapies and outcomes, with variations according …
SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy
X Ji, Y Liu, F Mei, X Li, M Zhang, B Yao, R Wu, J You… - Scientific reports, 2021 - nature.com
The screening of non-small cell lung cancer (NSCLC) tumors for anaplastic lymphoma
receptor tyrosine kinase (ALK) gene rearrangements is important because of the …
receptor tyrosine kinase (ALK) gene rearrangements is important because of the …
Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 …
A Nambirajan, R Sood, W Khatoon… - … of Pathology & …, 2024 - meridian.allenpress.com
Context.—ALK and ROS1 rearrangements are essential biomarkers to be tested in
advanced lung adenocarcinomas. While D5F3 Ventana assay is a companion diagnostic for …
advanced lung adenocarcinomas. While D5F3 Ventana assay is a companion diagnostic for …
Optimal care for patients with anaplastic lymphoma kinase (ALK)–Positive non–small cell lung cancer: a review on the role and utility of ALK inhibitors
A Singh, H Chen - Cancer management and research, 2020 - Taylor & Francis
The treatment of advanced non–small-cell lung cancer (NSCLC) has undergone a paradigm
shift in the last decade. Molecular characterization of the disease has led to the rapid …
shift in the last decade. Molecular characterization of the disease has led to the rapid …
Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase–and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India
PURPOSE Targeted therapies, such as crizotinib and ceritinib, have shown promising
results in treating non–small cell lung cancer (NSCLC) with specific oncogenic drivers like …
results in treating non–small cell lung cancer (NSCLC) with specific oncogenic drivers like …
Clinical outcomes of ALK+ non-small cell lung cancer in Denmark
KH Hansen, JS Johansen, EM Urbanska… - Acta …, 2023 - Taylor & Francis
Background Real-world clinical outcomes of anaplastic lymphoma kinase positive (ALK+)
non-small cell lung cancer (NSCLC) patients vary. This study aimed to investigate the …
non-small cell lung cancer (NSCLC) patients vary. This study aimed to investigate the …
Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a …
Abstract Objectives Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma
Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) are the preferred treatment option for patients …
Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) are the preferred treatment option for patients …
Taiwan Nationwide Study of First-Line ALK–TKI Therapy in ALK-Positive Lung Adenocarcinoma
ZR Zheng, JJ Wu, CJ Chiang, TI Chen, KC Chen… - Targeted Oncology, 2024 - Springer
Background The clinical outcomes of patients with anaplastic lymphoma kinase-positive
(ALK+) advanced lung adenocarcinoma vary according to real-world data. Objective In this …
(ALK+) advanced lung adenocarcinoma vary according to real-world data. Objective In this …
[HTML][HTML] Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: Results from the Spanish early access program
R Bernabé-Caro, P Garrido, R García-Campelo… - Oncotarget, 2022 - ncbi.nlm.nih.gov
This retrospective observational study analyzed the clinical characteristics, treatment
patterns and outcomes of 120 patients with advanced ALK-positive non-small-cell lung …
patterns and outcomes of 120 patients with advanced ALK-positive non-small-cell lung …